In-vitro plasma protein binding of propafenone and protein profile in eight mammalian species.

The research focuses on studying how propafenone, a medicine used primarily to treat irregular heartbeats, binds to plasma proteins of different mammalian species including humans. The findings suggest differing behaviours across species and highlight potential variances in how propafenone may affect different animals.

Protein Binding of Propafenone Across Species

• Plasma protein binding of propafenone was investigated in eight different mammals—mouse, rat, rabbit, dog, sheep, human, cow, and horse.
• The drug was found to be highly bound to plasma proteins across all these species, with binding percentages ranging from 86 to 99 percent.
• No significant correlation was found between free unbound propafenone and the different protein fractions in the plasma, suggesting that the drug binds highly and indiscriminately across the protein spectrum.

Concentration-dependency and Species Variations

• In some species like mouse, sheep, human, and horse, the free unbound portion of propafenone increases when the concentration of the drug is raised, revealing a concentration-dependency.
• This suggests that the drug’s effectiveness could potentially increase with an increase in dosage for these specific species. However, it’s important to note that an increase in dosage could also lead to more severe side effects or toxicities.
• Qualitative and quantitative differences were noted in the protein plasma profiles across the different species studied. This implies that each species’ plasma proteins possess unique features that can impact the drug’s behaviour.

Impact on Pharmacological Activity

• The study suggests that the protein plasma profile and propafenone concentration can influence the free fraction of the drug to varying degrees in different species. This free fraction refers to the amount of the drug that is available to exert its pharmacological effect.
• This variation can imply that the same plasma concentration of propafenone might result in varying levels of pharmacological activity across different species, despite the consistent high level of protein binding.
• These findings indicate that variations in the plasma protein binding abilities between species could lead to differences in the drug’s therapeutic effect, efficacy, and side effects.